Balaji Amines Ltd Q2FY26 Results: When Chemical Reactions Meet Market Reactions (Revenue ₹341 Cr, PAT ₹37 Cr, OPM 18%)
1. At a Glance
Balaji Amines Ltd — the aliphatic amine giant of India — just cooked up another quarter of mixed chemistry. With a Q2FY26 consolidated revenue of ₹341 crore and PAT of ₹37 crore, the numbers look decent until you peek at the YoY reality: sales dipped ~2%, and profit tumbled nearly 16%. The stock, meanwhile, is hanging around ₹1,258, down almost 19% in the last three months — clearly, investors are no longer high on amines. The company’s market cap of ₹4,073 crore might look solid, but with ROE of 8.83% and ROCE of 11%, it’s clear the chemical reaction has lost some fizz.
Still, it’s nearly debt-free (debt ₹31 crore, D/E 0.02), which means no bankers breathing down management’s neck — only shareholders wondering when the “Mega Project” status will start translating into mega profits.
Ever wondered how a company with four massive plants, 50+ export countries, and India’s largest amine capacity manages to make just 9% returns on equity? Welcome to the world of chemical cyclicality, where one quarter you’re making solvents for rocket fuel, and the next you’re watching the Chinese dump prices like Diwali clearance sales.
2. Introduction
There are companies that make products, and then there are companies like Balaji Amines — which make things that make things. From pharma intermediates to agrochemical precursors, this Solapur-based company has been stirring India’s industrial cauldron since before “Make in India” was even a campaign slogan.
But lately, the brew seems a little watered down. The company’s topline fell 10.8% over the past year, and profits shrank nearly 28%. The management blames “weak demand from pharma and agrochemical sectors” and “dumping from China.” Fair — because nothing unites Indian manufacturers faster than blaming China.
Despite the slowdown, Balaji keeps expanding — a ₹750 crore capex in subsidiary Balaji Specialty Chemicals Ltd, a 20 MW solar power project, and a new Isopropylamine (MIPA/DIPA) plant all under way. If chemical engineering were a Bollywood saga, Balaji’s script would be “Kabhi Cash Flow, Kabhi Capex.”
The silver lining? The company remains debt-free, has a high current ratio of 5.17, and its management still owns 54.6% of the business. So yes, the balance sheet still smells more of ethanol than panic.
3. Business Model – WTF Do They Even Do?
Balaji Amines isn’t your neighborhood chemical trader. It’s the largest manufacturer of aliphatic amines and their derivatives in India, serving sectors from pharma to rocket fuel (yes, literally).
The core business is split into two segments:
Amines & Specialty Chemicals (98% of revenue): This includes Methylamines, Ethylamines, and their derivatives — used in pharma, agro, rubber, and solvents. Big clients include Cipla, Lupin, Sun Pharma, and Indian Oil. Think of Balaji as the silent chemical wingman behind every antibiotic and pesticide you use.
Hotel Division (2-3% of revenue): Yes, you read that right. Amid tanks of methanol and reactors of acetonitrile, Balaji also runs a five-star hotel — the Balaji Sarovar Premiere in Solapur. With a 69% occupancy rate and ₹4,957 average room rate, the hotel earns respectable margins. Clearly, when chemicals don’t pay, hospitality takes over.
With 4 manufacturing plants totaling 2.86 lakh MTPA capacity and a new 1.3 lakh TPA expansion, Balaji is set to become India’s amine kingpin — if demand revives. Right now, global destocking and dumping are hurting realizations. But as management hopes, FY25 could be the detox year before things get aromatic again.
